ENCN

Dedicated to developing
effective and accessible
immunotherapeutics and extend
the life of cancer patients

More

Oricell Announces FDA
Clearance of IND Application for OriCAR-017
a novel GPRC5D Targeted CAR-T Cell Therapy
Utilizing the Company’s Proprietary Platform
for the Treatment of Relapsed/Refractory Multiple Myeloma.

More

Dedicated to developing effective and accessible
immunotherapeutics for global unmet clinical needs.

Dedicated to developing
effective and accessible
immunotherapeutics for
global unmet clinical needs.

With the long-term development strategy of developing innovative and clinically valuable cellular medicines, and through Oricell's proprietary technology platforms, we focus on global unmet clinical needs including hepatocellular carcinoma, multiple myeloma, gastric carcinoma, pancreatic carcinoma, cholangiocarcinoma and ovarian carcinoma. Seeking to provide doctors and patients with safer and more effective oncology treatment solutions.

  • OriCAR-017

    ·A GPRC5D targeting CAR-T for relapsed or refractory MM with promising clinical results, presented at 2022 ASCO and EHA

    ·Received FDA IND Approval in Jan 2023

    ·Received NMPA IND Approval in Aug 2023

    ·Received FDA Orphan Drug Designation in Oct 2022

    ·Follow-up data published on The Lancet Haematology

  • Ori-C101

    ·A GPC3 targeting CAR-T for advanced HCC with encouraging clinical results, presented at 2021 ASCO

    ·NMPA IND Approved in Sep 2022

    ·Clinical trial is initiated

Cutting-edge and synergistic technology platforms
Driving cancer immunotherapy to new heights

Cutting-edge and synergistic
technology platforms
Driving cancer immunotherapy
to new heights

Our proprietary OriAb and OriCAR technology platforms have made significant progress in antibody screening and optimization, improvement of the tumor immune microenvironment, and efficient T-cell infiltration and persistent killing ability, providing a solid basis for innovative cellular drugs. The proprietary and efficiently synergized technology platforms are the engine that drives our innovation and development, enabling us to take a leading position in the development of innovative drugs.

In the future, we will continue to invest in the development of innovative cellular drugs to provide more effective and safe therapeutic options for patients around the world.

  • OriAb

    ·1011 human naïve phage-display library

    ·1011 synthetic nanobody library

  • OriCAR

    ·High memory T cells ratio

    ·Superior anti-tumor activity

  • CMC Capabilities

    ·Experienced in cell-based bioassay development

    ·In-depth knowhow for product development and optimization

    ·Scale-out capability CAR-T cell production to meet clinical needs

Play video

Using innovative propriety technologies
to build the engine that drives our core
competitiveness

Using innovative propriety
technologies to build the
engine that drives our core
competitiveness

  • 100+

    Patents applied
    globally

  • 20+

    Countries and
    regions covered

  • 10+

    Registered
    trademarks

Columbia

Hong Kong

Australia

Russia

Malaysia

Israel

Brazil

Ukraine

USA

India

Philippines

Singapore

South Africa

Chile

South Korea

New Zealand

Japan

China

Mexico

Europe

Latest News

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company’s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma

SHANGHAI, NEW JERSEY, Jan 29th, 2024 – Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for OriCAR-017 for patients with relapsed/refractory multiple myeloma (R/R MM). OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D. The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells. The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately.

2024-01-29
Oricell Presented at 42nd Annual J.P. Morgan Healthcare Conference

Led by Co-founder & CEO, Helen Yang, and Co-founder & CSO, Dr. Peter He, the executive team represented Oricell and showcased our latest advancements. Peter specifically highlighted the positive strides made with our flagship asset, OriCAR-017, a GPRC5D-targeted CAR-T therapy. Concurrently, he elaborated on the company's significant progress in global development strategy, expressing unwavering confidence in our future path.

2024-01-12
Oricell filed OriCAR-017 IND to the FDA today

We are excited to announce that we have filed IND application of OriCAR-017 to the FDA on this day. Oricell continues to execute strategies and deliver progress on time. In 2023, we completed tech transfer from China to US and filed IND of OriCAR-017 in 7 months since preparation began.

2023-12-29
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

Shanghai, China—August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma (R/R MM). This remarkable milestone not only marks the world's first GPRC5D-targeting CAR-T therapy approved in China but also underlines Oricells prowess as a frontrunner in the biotech industry.

2023-08-10
Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28th, 2023 -- Oricell Therapeutics Co., Ltd (“Oricell” or “the Company”), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a $45M Series B1 investment round after the completion of a $125M Series B fund-raise in July 2022.

2023-02-28
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in

SHANGHAI, Jan. 31, 2023 - Oricell Therapeutics Co., Ltd (Oricell), an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, today announced publication of data from a clinical study evaluating the efficacy of OriCAR-017, an autologous GPRC5D-directed CAR-T cell therapy, in the treatment of relapsed/refractory multiple myeloma (RRMM) in an article entitled “Phase 1 Open-Label Single-Centre Single Arm Study of GPRC5D CAR T Cells(OriCAR-017) in Patients with Relapsed/Refractory Multiple Myeloma (POLARIS)” in The Lancet Haematology (2022 impact factor: 30.153).

2023-01-31
Oricell's GPRC5D CAR-T receives Orphan Drug Designation from FDA

Shanghai, Oct. 25, 2022 -- Oricell Therapeutics (Shanghai) Co., Ltd. ("Oricell" or "the company”) announced that the United States (U.S) Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation (ODD) to Oricell's proprietary CAR-T cell therapy targeting GPRC5D (OriCar-017) for the treatment of Relapsed/Refractory Multiple Myeloma (R/R MM).

2022-10-26

Dedicated to developing innovative cell
therapy for unmet medical needs globally